Compare AWR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWR | NAMS |
|---|---|---|
| Founded | 1929 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1998 | 2022 |
| Metric | AWR | NAMS |
|---|---|---|
| Price | $90.27 | $27.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $84.00 | $46.75 |
| AVG Volume (30 Days) | 224.8K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | 6.31 | ★ 32.81 |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $658,073,000.00 | $22,503,000.00 |
| Revenue This Year | $5.20 | $17.96 |
| Revenue Next Year | $2.27 | $540.65 |
| P/E Ratio | $48.98 | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $69.45 | $23.05 |
| 52 Week High | $91.11 | $42.21 |
| Indicator | AWR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 42.95 |
| Support Level | $71.52 | $25.88 |
| Resistance Level | N/A | $28.97 |
| Average True Range (ATR) | 1.53 | 1.01 |
| MACD | 0.20 | 0.17 |
| Stochastic Oscillator | 93.67 | 47.13 |
American States Water Co is a water and utilities holding company based in California. The segments of the firm include water, electric, and contracted services. Within these segments, American States Water conducts water and electric operations through Golden State Water Company and Bear Valley Electric Service, Inc while contracted services through American States Utility Services and its subsidiaries. Golden State Water conducts its operations across various counties in California and is regulated by the California Public Utilities Commission. American States Utility Services has contracted with the U.S. government to provide water services to various military installations. The majority of the company's revenue is derived from water services to commercial and residential customers.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.